Targeting proteostasis dysfunction in Alzheimer’s disease using small molecule modulators

Alzheimer's disease (AD) is a progressive neurodegenerative disease marked by the aggregation of amyloid-β (Aβ) peptides and hyperphosphorylated tau, disruption of protein homeostasis (proteostasis), synaptic impairment, and cognitive decline. Growing evidence suggests that the impaired clearance of Aβ, rather than their overproduction, is a significant contributor to the pathogenesis of AD. This…